Ultrasound Guided Thoracic Paravertebral Block for Hepatic Tumors Ablation
NCT ID: NCT02271646
Last Updated: 2019-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2014-08-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TPVB is suitable for unilateral operations. And it is increasing popular nowadays because of using ultrasound guided which make it is more reliable and has less side effects especially the severe one such as pneumothorax. To cover all nerve supply liver, we decided to use right TPVB at T5-6, T7-8, and T9-10.
The aim of this study is to prove that TPVB can provide an effective pain control for patients undergo liver RFA both at rest and movement (cough). We are going to measure the pain score at recovery room and the effective pain control means patients has mild pain (pain score less \</= 3 and do not ask for analgesic drugs).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Paravertebral Block for Percutaneous Radiofrequency Ablation of Liver Lesions
NCT01812577
Is Thoracic Paravertebral Block a Better Option Than Conscious Sedation for PRFA of Liver Tumors
NCT04241887
Application of Ultrasound-Guided Thoracic Paravertebral Block in Pulmonary Ablation Surgery
NCT05437718
Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain of Hepatectomy With Right J-shape Subcostal Incision
NCT02817321
Rhomboid Intercostal Block for Video Assisted Thoracic Surgery
NCT04428216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.5% marcaine 20ml
3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
0.5% marcaine 20ml
3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.5% marcaine 20ml
3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergo percutaneous radiofrequency ablation for liver tumors
* ASA classification 1-3
Exclusion Criteria
* Chronic abdominal pain \> 1 week
* Regular analgesic drugs use
* Infection at back (Block area)
* Severe spinal deformity
* PT \> 16 sec, aPTT \> 32, platelet \< 50,000/cumm
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Siriraj Hospital
OTHER
Mahidol University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pawinee Pangthipampai, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mahidol University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Siriraj hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
(IO) R015731063
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
070/2557(EC2)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.